Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Landskrona – page 78

1 405 clinical trials in Landskrona, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Landskrona at a glance
1 405
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 405 trials in Landskrona

Open in trial search

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cardiac amyloidosis

Not recruiting

Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Neoplasm

Not recruiting

Study on the Safety and Effects of RP-1664 for Patients with Advanced Solid Tumors

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RP-1664 sulfate
  • Sponsor:Repare Therapeutics USA Inc.

Giant cell arteritis

Not recruiting

Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Breast cancer+1

Not recruiting

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Seagen Inc.

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Medivation Inc.

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Landskrona

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure with preserved ejection fraction (HFpEF), evaluating the effectiveness of spironolactone and eplerenone treatments combined with standard care approaches.

  • Heart Failure Management
  • Cardiovascular Outcomes
  • Treatment Optimization

The research aims to reduce hospitalization rates and improve cardiovascular survival outcomes through registry-based methodologies.

02 Urological Oncology

Groundbreaking research in non-muscle invasive bladder cancer treatment, comparing the efficacy of adjuvant therapies using gemcitabine versus mitomycin in intermediate-risk cases.

  • Bladder Cancer Treatment
  • Recurrence Prevention
  • Post-surgical Care

This study focuses on improving recurrence-free survival rates following transurethral tumor resection procedures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.